Nkarta (NKTX) projected to post quarterly earnings on Tuesday. August 4, 2026 Key points. * Nkarta is expected to report Q2 2026 results before the market opens on August 11, with analysts forecasting a loss of $0.39 per share. The company previously reported a smaller-than-expected loss of $0.37 per share in Q1. * NKTX shares recently traded at $2.21, well below the analyst consensus price target of $10.75. The stock has a market capitalization of approximately $158 million and has ranged from $1.70 to $3.72 over the past year. * Analyst sentiment is mixed but leans positive, with a consensus "Moderate Buy" rating, while institutional investors and hedge funds own 80.54% of the stock. Nkarta is developing off-the-shelf CAR-NK therapies, led by its early-stage NKX019 program for B-cell malignancies. * MarketBeat previews the top five stocks to own by September 1st. Nkarta (NASDAQ:NKTX - Get Free Report) is expected to post its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect Nkarta to announce earnings of ($0.39) per share for the quarter. Interested persons are encouraged to explore the company's upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 4:00 PM ET. Nkarta (NASDAQ:NKTX - Get Free Report) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.37) EPS for the quarter, topping analysts' consensus estimates of ($0.39) by $0.02. On average, analysts expect Nkarta to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year. Nkarta stock performance. Nkarta stock traded up $0.07 during mid-day trading on Tuesday, reaching $2.21. 148,492 shares of the company were exchanged, compared to its average volume of 762,760. The business has a fifty day moving average of $2.76 and a 200 day moving average of $2.57. The firm has a market cap of $158.46 million, a P/E ratio of -1.65 and a beta of 0.93. Nkarta has a 12-month low of $1.70 and a 12-month high of $3.72. Institutional inflows and outflows. Hedge funds have recently added to or reduced their stakes in the business. GSK plc acquired a new position in shares of Nkarta in the 4th quarter valued at $5,829,000. Jane Street Group LLC lifted its position in Nkarta by 118.7% during the 1st quarter. Jane Street Group LLC now owns 134,286 shares of the company's stock worth $247,000 after acquiring an additional 852,559 shares during the period. Millennium Management LLC acquired a new stake in Nkarta during the 3rd quarter worth about $1,549,000. Renaissance Technologies LLC grew its stake in Nkarta by 48.6% during the 4th quarter. Renaissance Technologies LLC now owns 1,702,022 shares of the company's stock valued at $3,149,000 after purchasing an additional 556,945 shares during the last quarter. Finally, AQR Capital Management LLC increased its holdings in shares of Nkarta by 300.5% in the first quarter. AQR Capital Management LLC now owns 672,078 shares of the company's stock valued at $1,237,000 after purchasing an additional 504,272 shares during the period. 80.54% of the stock is owned by institutional investors and hedge funds. Wall Street analysts forecast growth. Several research firms have recently commented on NKTX. Needham & Company LLC reissued a "buy" rating and issued a $11.00 price target on shares of Nkarta in a research report on Wednesday, May 13th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Nkarta in a research report on Wednesday, June 24th. Wall Street Zen upgraded Nkarta from a "strong sell" rating to a "sell" rating in a research note on Sunday. Evercore set a $9.00 target price on shares of Nkarta in a report on Monday, May 18th. Finally, TD Cowen assumed coverage on shares of Nkarta in a research report on Tuesday, June 23rd. They set a "buy" rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $10.75. Discover more Stocks & Bonds ETF Screener Tool Options Profit Calculator Nkarta company profile. Nkarta, Inc is a clinical-stage biotechnology company specializing in the development of off-the-shelf natural killer (NK) cell therapies for the treatment of cancer. Leveraging proprietary activation and expansion technologies, Nkarta aims to harness the innate tumor-killing properties of NK cells while incorporating targeted immuno-engineering approaches to enhance safety, potency and persistence in patients. The company's platform supports both allogeneic cell manufacturing and genetic modifications to generate chimeric antigen receptor-expressing NK cell candidates designed to address a range of hematologic and solid tumors. Nkarta's lead program, NKX019, is an anti-CD19 CAR-NK cell therapy in early-phase clinical trials for relapsed or refractory B-cell malignancies. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Nkarta, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nkarta wasn't on the list. While Nkarta currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Nkarta, an early-stage biotech company, held $230 million in cash as of March 2026 with no debt, giving it a 2.6-year cash runway based on its trailing twelve-month cash burn of $88 million. The company reduced its cash burn by 16% over the past year, suggesting management is maintaining steady business development with slightly lower spending. Nkarta recorded no revenue during this period, indicating it remains in early development stages. As a publicly listed company, Nkarta has access to capital markets and could raise additional funding through equity issuance or debt if needed to extend its runway or accelerate growth.

Nkarta to participate in Needham Virtual Healthcare Conference. Rhea-AI Impact Rhea-AI Sentiment Rhea-AI summary. Nkarta (Nasdaq: NKTX) will participate in the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. CEO Paul Hastings will join a panel at 11:45 a.m. ET on "Cell Therapy in Autoimmune." President Nadir Mahmood will deliver a fireside chat at 3:45 p.m. ET covering updates on Nkarta's investigational CAR-NK therapy for B cell-mediated autoimmune diseases. A simultaneous webcast of the fireside chat will be available on the company's Investors website, with a replay archived for approximately 90 days. News market reaction - NKTX. Key figures. Panel time: 11:45 a.m. ET Fireside chat time: 3:45 p.m. ET Conference edition: 25th Annual +1 more Market reality check. Price: $2.29 Vol: Volume 285,200 is 50% of... Peers on argus. NKTX is up 2.67%, while close biotech peers show mixed moves (e.g., AGEN up 0.24... Historical context. 5 past events · Latest: Mar 25 (Positive) Pattern 5 events Regulatory & risk context. Active S-3 Shelf · $350,000,000 Shelf Active Market pulse summary. This announcement highlights Nkarta's continued participation in high-visibility healthcare conferen... Key terms. natural killer (nk) cell therapies, car-nk cell therapy, b cell-mediated autoimmune diseases AI-generated analysis. Not financial advice. 04/09/2026 - 07:00 AM SOUTH SAN FRANCISCO, Calif., April 09, 2026 (GLOBE NEWSWIRE) - Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the 25th Annual Needham Virtual Healthcare Conference. At 11:45 a.m. ET on Wednesday, April 15, Nkarta CEO Paul Hastings will participate in a virtual panel discussion, "Cell Therapy in Autoimmune: State of the Art and What Comes Next." Later that afternoon, Nkarta President Nadir Mahmood will participate in a 3:45 p.m ET fireside chat to share updates on the company's investigational CAR-NK cell therapy to treat B cell-mediated autoimmune diseases. A simultaneous webcast of the fireside chat will be available on the Investors section of Nkarta's website, and a replay will be archived on the website for approximately 90 days. About Nkarta Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company's website at www.nkartatx.com. Nkarta Media/Investor Contact: Nadir Mahmood Nkarta, Inc. [email protected] Faq. When will Nkarta (NKTX) present at the Needham Virtual Healthcare Conference on April 15, 2026? Nkarta will present on April 15, 2026 with two scheduled appearances during the virtual conference. According to the company, CEO Paul Hastings speaks at 11:45 a.m. ET and President Nadir Mahmood at 3:45 p.m. ET. How can investors watch Nkarta's (NKTX) fireside chat at the Needham conference? Investors can watch the fireside chat via a simultaneous webcast on Nkarta's Investors website. According to the company, the live webcast will be posted and a replay archived on the site for about 90 days. What topics will Nkarta (NKTX) cover at the Needham Virtual Healthcare Conference? Nkarta will discuss cell therapy approaches for autoimmune disease and its CAR-NK program for B cell-mediated conditions. According to the company, the sessions include a panel on Cell Therapy in Autoimmune and a fireside chat with program updates. Who from Nkarta (NKTX) will speak at the Needham Virtual Healthcare Conference? Nkarta's CEO Paul Hastings and President Nadir Mahmood will speak on April 15, 2026 at the virtual conference. According to the company, Hastings joins a panel and Mahmood leads a 3:45 p.m. ET fireside chat. Will a replay of Nkarta's (NKTX) Needham presentation be available after the conference? Yes. A replay of the fireside chat will be archived on Nkarta's Investors website for approximately 90 days. According to the company, the replay will be accessible following the live event for investor review.